ADA 2026: The Research Moments That Will Reshape Clinical Practice
The American Diabetes Association’s 2026 Scientific Sessions produced a concentrated set of technology findings that are already influencing how clinicians think about CGM deployment beyond its traditional insulin-dependent diabetes management context. diatribe’s reporting on diabetes technology highlights from ADA 2026 identified three themes with the most direct clinical practice implications: the expanded use of CGM for people with Type 2 diabetes to help avoid hospitalisation from diabetic ketoacidosis; the simplification of diabetes management for people on multiple daily injections who can now rely on CGM data in ways that previously required more complex systems; and Abbott’s presentation showing that nearly half of DKA cases are not recognised when a patient is admitted to hospital — a diagnostic gap that the Libre Duo, combining glucose and ketone monitoring in a single wearable sensor, is specifically designed to address. Abbott announced European approval for the Libre Duo and Libre Duo 10 Day at ADA — the first sensors in commercial availability designed to track both glucose and ketones simultaneously.
Omnipod 5 and Libre 3 Plus: Closed-Loop Integration Getting Closer
One of the most practically significant developments for insulin-using diabetes patients in 2026 is the approaching pairing of Insulet’s Omnipod 5 automated insulin delivery system with Abbott’s FreeStyle Libre 3 Plus CGM. diatribe’s diabetes technology news tracking confirmed that Omnipod 5 will pair with Libre 3 Plus sometime in 2026, bringing together what are arguably the two most user-friendly platforms in their respective categories. The Libre 3 Plus is Abbott’s most advanced system, offering glucose readings every minute and a 14-day wear time, FDA-approved for people with diabetes aged two and above. The device is approximately the size of two stacked pennies — meaningfully smaller than its predecessor — addressing one of the persistent user-experience friction points in CGM adoption. For patients currently using the Libre CGM ecosystem who prefer Omnipod’s tubeless pod delivery over traditional pump therapy, the integration eliminates a compatibility barrier that previously required choosing between preferred CGM and preferred delivery system.
Senseonics’ Eversense 365: The World’s First One-Year CGM
The most technically distinctive product development in the CGM category in 2026 is Senseonics’ Eversense 365 — a one-year implantable CGM that received FDA approval and is now commercially available, making it the world’s first CGM designed to operate for a full year without replacement. Type1Strong’s 2026 CGM guide documented the device’s distinguishing clinical characteristics: unlike all other CGM systems, Eversense features a removable transmitter that can be taken on and off without wasting a CGM sensor or requiring a fresh warm-up period, as the sensor itself remains implanted throughout the year. The device requires only a single annual warm-up period rather than the repeated warm-up cycles associated with external sensor replacements. For patients who experience sensor fatigue — the friction of replacing wearable sensors every 10 to 15 days, managing adhesive irritation, and repeating warm-up periods — a once-yearly implant procedure with year-long continuous monitoring represents a fundamentally different quality-of-life proposition. The clinical trade-off is the implant procedure itself, which requires a trained healthcare provider, but for motivated patients with adequate healthcare access this trade-off is increasingly viewed as worthwhile.
Medicare’s Expanding Coverage: The Reimbursement Tailwind
The diabetes care devices market’s most structurally significant commercial development in 2026 is not a new product but a reimbursement expansion. The Imaging Wire’s analysis noted that expanded Medicare coverage for Type 2 basal-only patients, combined with accelerating over-the-counter approvals, is materially expanding the CGM addressable market in 2026. Dexcom’s Stelo — the first FDA-cleared over-the-counter CGM, approved for non-insulin-using Type 2 diabetes patients and wellness users with a 15-day sensor life purchasable without a prescription — represents the commercial expression of this coverage expansion. Abbott received FDA clearance in June 2024 for two OTC CGM systems, Lingo and Libre Rio, based on its FreeStyle Libre technology platform, enabling non-prescription access and expanding reach beyond traditional diabetes care into consumer health monitoring. The growth in OTC-accessible CGM is the market’s fastest-expanding segment, reflecting the convergence of regulatory accessibility and consumer wellness demand.
Abbott’s Manufacturing Issue: A Safety Signal in 2025 Resolved
Any honest account of the CGM market in 2026 must acknowledge the Abbott FreeStyle Libre 3 and Libre 3 Plus sensor recall that occurred in late 2025 following the identification of a manufacturing issue. Type1Strong’s 2026 CGM guide confirmed that Abbott identified and resolved the manufacturing problem, resulting in a Medical Device Correction, and that consumers could visit FreeStyleCheck.com to determine whether their sensors were affected and to receive replacements at no charge. The issue has been resolved, and the Libre 3 Plus remains FDA-cleared and commercially available in 2026. Separately, in 2025, the FDA issued recalls for certain Dexcom G7 receivers, which the company similarly addressed and resolved. Both recalls were identified and corrected through the regulatory surveillance mechanisms that the FDA maintains for cleared medical devices, and both companies’ flagship CGM systems are available and recommended across 2026 clinical and consumer contexts.
What the Diabetes Care Devices Market Looks Like at the Convergence of OTC and Clinical
Constancy Researchers’ assessment: the diabetes care devices market in 2026 is undergoing the most significant structural evolution in its history since the introduction of real-time CGM, driven by the convergence of three developments whose interaction is compounding their individual commercial impact. OTC CGM access is removing the prescription barrier that previously restricted the technology to diagnosed and managed diabetes patients, opening a vast consumer wellness market. Medicare’s expanded coverage of CGM for Type 2 basal-only patients is bringing reimbursement infrastructure to the largest untapped clinical CGM patient segment. And integrated automated insulin delivery — closed-loop systems pairing CGM data with insulin pump algorithms — is progressively removing the cognitive burden of diabetes management in a way that insulin injections and fingerstick monitoring never could. The Omnipod 5-Libre 3 Plus integration, the Senseonics Eversense 365’s one-year wear horizon, and Abbott’s dual glucose-ketone Libre Duo are three distinct product innovations addressing three distinct patient experience friction points simultaneously — and the market rewards for doing so are structurally secure.
Looking to navigate geopolitical risks and identify new industry opportunities?
Connect with Constancy Researchers for data-driven insights, geopolitical intelligence, and strategic consulting tailored to your business needs.
